Cingulate Therapeutics News and Activities

Presence

Cingulate Therapeutics develops medicines for brain health conditions. Its main products are prescription drug candidates and delivery technologies for patients, healthcare providers, and pharmaceutical partners.

Cingulate Therapeutics products and services overview:

Prescription medicines
Drug delivery
ADHD treatments
Anxiety treatments

Revenue: ~$0 million

Employees: 20

Headquarters: Kansas City, United States (USA)

Cingulate Therapeutics is one of the...

Cingulate Therapeutics is a company listed under the stock ticker CING (US).

Executives

View the org chart displaying its 18 main executives

Most searched biographies at Cingulate Therapeutics

Popular executive movements at Cingulate Therapeutics

Jay Roberts, Executive Chairman of the Board, has left the company (posted on May 20 2026).
Jeff Hargroves has joined the company as Director (posted on May 20 2026).
Jeff Ervin, Director, has left the company (posted on May 20 2026).

Click here to view some more movements at Cingulate Therapeutics

Create your alert
to follow the executive moves at Cingulate Therapeutics.

Biotechnology

Cingulate Therapeutics has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
Tissium has just announced a $60 Million fundraising (posted on July 8 2026).